Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | RPS6KA2 | Q15349 | 14/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.47 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.47 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2983427 | 1.00 | HRH3 (0.55) | HRH3CYP3A4CYP2D6RPS6KA2RPS6KA3 | |
| SCHEMBL2983139 | 1.00 | HRH3 (0.55) | HRH3CYP3A4CYP2D6RPS6KA2RPS6KA3 | |
| SCHEMBL4041103 | 0.84 | HRH3 (0.56) | HRH3CYP3A4CYP2D6RPS6KA2RPS6KA3 | |
| SCHEMBL4044891 | 0.84 | HRH3 (0.56) | HRH3CYP3A4CYP2D6RPS6KA2RPS6KA3 | |
| SCHEMBL5352972 | 0.83 | HRH3 (0.55) | HRH3CYP3A4CYP2D6RPS6KA2RPS6KA3 | |
| SCHEMBL5352981 | 0.83 | HRH3 (0.55) | HRH3CYP3A4CYP2D6RPS6KA2RPS6KA3 | |
| SCHEMBL1979881 | 0.81 | RPS6KA2 (0.59) | HRH3CYP3A4CYP2D6RPS6KA2RPS6KA3 | |
| SCHEMBL31300701 | 0.81 | RPS6KA2 (0.59) | HRH3CYP3A4CYP2D6RPS6KA2RPS6KA3 | |
| SCHEMBL4045058 | 0.77 | HRH3 (0.49) | HRH3CYP3A4CYP2D6RPS6KA2RPS6KA3 | |
| SCHEMBL4045060 | 0.77 | HRH3 (0.49) | HRH3CYP3A4CYP2D6RPS6KA2RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786109-B2 | Tricyclic amide derivatives as modulators of H3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1960401-B1 | TRICYCLIC AMIDE DERIVATIVES USEFUL FOR TREATING OBESITY | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-7579351-B2 | Tricyclic amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090156583-A1 | Tricyclic Amide Derivatives | NETTEKOVEN MATTHIAS | 2009-06-18 | — | — | US | disclosed |
| EP-1960401-A1 | TRICYCLIC AMIDE DERIVATIVES USEFUL FOR TREATING OBESITY | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070135416-A1 | Tricyclic amide derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2007065820-A1 | TRICYCLIC AMIDE DERIVATIVES USEFUL FOR TREATING OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156583-A1 | Tricyclic Amide Derivatives | HRH4, HRH3, HCAR1 | HRH3 2/4885CYP3A4 793/4885CYP2D6 931/4885 |
| US-20070135416-A1 | Tricyclic amide derivatives | HRH4, HRH3, HCAR1 | HRH3 2/4885CYP3A4 793/4885CYP2D6 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.